<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"	
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:media="http://search.yahoo.com/mrss/"
	>
<channel>
	<title>HIV/AIDS &#187; The Doctor&#039;s Channel</title>
	<atom:link href="http://www.thedoctorschannel.com/channels/hiv-aids/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.thedoctorschannel.com</link>
	<description>Internet TV for Doctors</description>
	<lastBuildDate>Wed, 16 May 2012 23:34:19 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
			<item>
		<title>The month after ACS risky for patients with HIV</title>
		<link>http://www.thedoctorschannel.com/view/the-month-after-acs-risky-for-patients-with-hiv/</link>
		<pubDate>Tue, 10 Jan 2012 23:56:39 +0000</pubDate> 
				<category><![CDATA[Cardiology]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[acute coronary syndrome]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[MI]]></category>
		<category><![CDATA[myocardial infarction]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22915</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Patients with HIV infection who are admitted to the hospital with acute coronary syndrome (ACS) face a “substantial” risk of dying in the short-term and a significant risk of needing revascularization and suffering myocardial infarction in the longer term, new research suggests. To mitigate these risks, close attention to modifiable -]]></description>
		
			<media:content duration="1:44" medium="video">
		<media:title><![CDATA[The month after ACS risky for patients with HIV]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Patients with HIV infection who are admitted to the hospital with acute coronary syndrome (ACS) face a “substantial” risk of dying in the short-term and a significant risk of needing revascularization and suffering myocardial infarction in the longer term, new research suggests. To mitigate these risks, close attention to modifiable -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/the-month-after-acs-risky-for-patients-with-hiv/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/01/Screen-shot-2012-01-10-at-5.55.38-PM.png"/>
	<media:keywords><![CDATA[ACS,acute coronary syndrome,HIV,MI,myocardial infarction]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Bone Health in the HIV-Infected Population</title>
		<link>http://www.thedoctorschannel.com/view/bone_health_video/</link>
		<pubDate>Sun, 01 Jan 2012 19:43:00 +0000</pubDate> 
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[Featured Information from Industry]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Information from Industry]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[bone]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[osteoarthritis]]></category>
		<category><![CDATA[Turner Overton]]></category>
		<category><![CDATA[University of Alabama]]></category>
		<category><![CDATA[virology]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=27733</guid>
		<description><![CDATA[Dr. Overton recently joined the Division of Infectious Diseases at the University of Alabama in Birmingham. He received his MD from the University of Tennessee in Memphis, Tennessee. He was an Internal Medicine resident at the University of Alabama in Birmingham. He completed his fellowship in Infectious Disease at Washington University School of Medicine and -]]></description>
		
			<media:content duration="22:24" medium="video">
		<media:title><![CDATA[Bone Health in the HIV-Infected Population]]></media:title>
	<media:description><![CDATA[Dr. Overton recently joined the Division of Infectious Diseases at the University of Alabama in Birmingham. He received his MD from the University of Tennessee in Memphis, Tennessee. He was an Internal Medicine resident at the University of Alabama in Birmingham. He completed his fellowship in Infectious Disease at Washington University School of Medicine and -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/bone_health_video/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2012/04/bone-health-screenshot.jpg"/>
	<media:keywords><![CDATA[AIDS,bone,HIV,osteoarthritis,Turner Overton,University of Alabama,virology]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Benefit of rituximab-EPOCH for HIV-related lymphoma confirmed</title>
		<link>http://www.thedoctorschannel.com/view/benefit-of-rituximab-epoch-for-hiv-related-lymphoma-confirmed/</link>
		<pubDate>Thu, 29 Dec 2011 21:33:51 +0000</pubDate> 
				<category><![CDATA[Hematology-Oncology]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[EPOCH]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[Rituximab]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22614</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab combined with EPOCH chemotherapy than rituximab plus CHOP chemotherapy.&#160; “Benefits were observed in both high-risk and low-risk patients,” note the authors of the report in Cancer online -]]></description>
		
			<media:content duration="1:28" medium="video">
		<media:title><![CDATA[Benefit of rituximab-EPOCH for HIV-related lymphoma confirmed]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – A pooled analysis of two trials indicates that HIV patients with aggressive B-cell non-Hodgkin lymphoma (NHL) fare better with a regimen of rituximab combined with EPOCH chemotherapy than rituximab plus CHOP chemotherapy.&#160; “Benefits were observed in both high-risk and low-risk patients,” note the authors of the report in Cancer online -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/benefit-of-rituximab-epoch-for-hiv-related-lymphoma-confirmed/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/Screen-shot-2011-12-29-at-4.31.56-PM.png"/>
	<media:keywords><![CDATA[chemotherapy,EPOCH,HIV,Rituximab]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>“Tail” regimens reduce viral resistance after intrapartum nevirapine in HIV-positive women</title>
		<link>http://www.thedoctorschannel.com/view/tail-regimens-reduce-viral-resistance-after-intrapartum-nevirapine-in-hiv-positive-women/</link>
		<pubDate>Tue, 27 Dec 2011 23:40:44 +0000</pubDate> 
				<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Neonatology]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[didanosine]]></category>
		<category><![CDATA[HAART]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[lopinavir]]></category>
		<category><![CDATA[nevirapine]]></category>
		<category><![CDATA[NVP]]></category>
		<category><![CDATA[ritonavir]]></category>
		<category><![CDATA[vertical transmission]]></category>
		<category><![CDATA[zidovudine]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22410</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – In pregnant HIV-infected women treated with a single intrapartum dose of nevirapine (NVP) to prevent vertical HIV transmission, the subsequent selection of nevirapine-resistant virus can be substantially reduced with various short-term antiretroviral “tail” regimens. The findings, reported in Clinical Infectious Diseases online December 5, come from a multinational trial conducted -]]></description>
		
			<media:content duration="1:48" medium="video">
		<media:title><![CDATA[“Tail” regimens reduce viral resistance after intrapartum nevirapine in HIV-positive women]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – In pregnant HIV-infected women treated with a single intrapartum dose of nevirapine (NVP) to prevent vertical HIV transmission, the subsequent selection of nevirapine-resistant virus can be substantially reduced with various short-term antiretroviral “tail” regimens. The findings, reported in Clinical Infectious Diseases online December 5, come from a multinational trial conducted -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/tail-regimens-reduce-viral-resistance-after-intrapartum-nevirapine-in-hiv-positive-women/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/Screen-shot-2011-12-27-at-6.38.27-PM.png"/>
	<media:keywords><![CDATA[didanosine,HAART,HIV,lopinavir,nevirapine,NVP,ritonavir,vertical transmission,zidovudine]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Moxifloxacin or amoxicillin/clavulanate effective for COPD exacerbations</title>
		<link>http://www.thedoctorschannel.com/view/moxifloxacin-or-amoxicillinclavulanate-effective-for-copd-exacerbations/</link>
		<pubDate>Tue, 27 Dec 2011 23:15:14 +0000</pubDate> 
				<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Neonatology]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[didanosine]]></category>
		<category><![CDATA[HAART]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[lopinavir]]></category>
		<category><![CDATA[nevirapine]]></category>
		<category><![CDATA[NVP]]></category>
		<category><![CDATA[ritonavir]]></category>
		<category><![CDATA[vertical transmission]]></category>
		<category><![CDATA[zidovudine]]></category>
		<guid isPermaLink="false">http://www.thedoctorschannel.com/?p=22393</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Moxifloxacin is as effective as amoxicillin/clavulanic acid in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD) in the outpatient setting, according to the results of the MAESTRAL trial reported in the European Respiratory Journal online December 1. “The good efficacy and tolerability of both drugs confirms their position -]]></description>
		
			<media:content duration="1:32" medium="video">
		<media:title><![CDATA[Moxifloxacin or amoxicillin/clavulanate effective for COPD exacerbations]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Moxifloxacin is as effective as amoxicillin/clavulanic acid in the treatment of exacerbations of chronic obstructive pulmonary disease (COPD) in the outpatient setting, according to the results of the MAESTRAL trial reported in the European Respiratory Journal online December 1. “The good efficacy and tolerability of both drugs confirms their position -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/moxifloxacin-or-amoxicillinclavulanate-effective-for-copd-exacerbations/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/Screen-shot-2011-12-27-at-6.22.39-PM.png"/>
	<media:keywords><![CDATA[didanosine,HAART,HIV,lopinavir,nevirapine,NVP,ritonavir,vertical transmission,zidovudine]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Amphotericin B plus fluconazole a good option for HIV-associated meningitis</title>
		<link>http://www.thedoctorschannel.com/view/amphotericin-b-plus-fluconazole-a-good-option-for-hiv-associated-meningitis/</link>
		<pubDate>Mon, 21 Nov 2011 20:57:00 +0000</pubDate> 
				<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[Bennett]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[meningitis]]></category>
		<category><![CDATA[National Institute of Allergy and Infectious Diseases]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Reuters]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/amphotericin-b-plus-fluconazole-a-good-option-for-hiv-associated-meningitis/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For the initial treatment of HIV-associated cryptococcal meningitis, amphotericin B plus fluconazole is a good alternative to amphotericin B plus flucytosine (5-FC), the current standard initial therapy, a study suggests. The study found no statistically significant difference in early fungicidal activity between amphotericin B plus fluconazole and amphotericin B plus -]]></description>
		
			<media:content duration="1:35" medium="video">
		<media:title><![CDATA[Amphotericin B plus fluconazole a good option for HIV-associated meningitis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For the initial treatment of HIV-associated cryptococcal meningitis, amphotericin B plus fluconazole is a good alternative to amphotericin B plus flucytosine (5-FC), the current standard initial therapy, a study suggests. The study found no statistically significant difference in early fungicidal activity between amphotericin B plus fluconazole and amphotericin B plus -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/amphotericin-b-plus-fluconazole-a-good-option-for-hiv-associated-meningitis/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4834.jpg"/>
	<media:keywords><![CDATA[AIDS,Bennett,HIV,meningitis,National Institute of Allergy and Infectious Diseases,News,Reuters]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>LAM assay not ready for routine use: review</title>
		<link>http://www.thedoctorschannel.com/view/lam-assay-not-ready-for-routine-use-review/</link>
		<pubDate>Tue, 26 Jul 2011 20:33:00 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Pulmonary Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[Dr. Dick Menzies]]></category>
		<category><![CDATA[European Respiratory Journal]]></category>
		<category><![CDATA[LAM assay]]></category>
		<category><![CDATA[lipoarabinomannan]]></category>
		<category><![CDATA[TB]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/lam-assay-not-ready-for-routine-use-review/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) &#8211; The lipoarabinomannan (LAM) urinary assay isn’t accurate enough to be used for routine TB diagnosis, according to a new review in the European Respiratory Journal. That’s despite hope that the test, originally produced by Chemogen and now marketed by Inverness Medical Innovations as Clearview TB ELISA, could replace less convenient, -]]></description>
		
			<media:content duration="1:35" medium="video">
		<media:title><![CDATA[LAM assay not ready for routine use: review]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) &#8211; The lipoarabinomannan (LAM) urinary assay isn’t accurate enough to be used for routine TB diagnosis, according to a new review in the European Respiratory Journal. That’s despite hope that the test, originally produced by Chemogen and now marketed by Inverness Medical Innovations as Clearview TB ELISA, could replace less convenient, -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/lam-assay-not-ready-for-routine-use-review/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4565.jpg"/>
	<media:keywords><![CDATA[Dr. Dick Menzies,European Respiratory Journal,LAM assay,lipoarabinomannan,TB]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Bone density stabilizes in HIV patients on HAART</title>
		<link>http://www.thedoctorschannel.com/view/bone-density-stabilizes-in-hiv-patients-on-haart/</link>
		<pubDate>Tue, 12 Jul 2011 19:08:00 +0000</pubDate> 
				<category><![CDATA[Endocrinology]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Radiology]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[BMD]]></category>
		<category><![CDATA[bone mineral density]]></category>
		<category><![CDATA[Dr. Mark Bolland]]></category>
		<category><![CDATA[HAART]]></category>
		<category><![CDATA[highly active antiretroviral therapy]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[Journal of Clinical Endocrinology and Metabolism]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/bone-density-stabilizes-in-hiv-patients-on-haart/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – For many patients with HIV receiving highly active antiretroviral therapy (HAART), routine bone mineral density (BMD) assessment may not be necessary because BMD stabilizes or increases over the long term, according to a report in the September issue of the Journal of Clinical Endocrinology and Metabolism online June 29. The -]]></description>
		
			<media:content duration="1:42" medium="video">
		<media:title><![CDATA[Bone density stabilizes in HIV patients on HAART]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – For many patients with HIV receiving highly active antiretroviral therapy (HAART), routine bone mineral density (BMD) assessment may not be necessary because BMD stabilizes or increases over the long term, according to a report in the September issue of the Journal of Clinical Endocrinology and Metabolism online June 29. The -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/bone-density-stabilizes-in-hiv-patients-on-haart/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4535.jpg"/>
	<media:keywords><![CDATA[BMD,bone mineral density,Dr. Mark Bolland,HAART,highly active antiretroviral therapy,HIV,Journal of Clinical Endocrinology and Metabolism]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Triple antiretroviral therapy improves pregnancy outcomes</title>
		<link>http://www.thedoctorschannel.com/view/triple-antiretroviral-therapy-improves-pregnancy-outcomes/</link>
		<pubDate>Thu, 30 Jun 2011 19:25:00 +0000</pubDate> 
				<category><![CDATA[Family Medicine]]></category>
		<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Ob/Gyn]]></category>
		<category><![CDATA[Pediatrics]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[AIDS]]></category>
		<category><![CDATA[Dr. Karin Nielsen-Saines]]></category>
		<category><![CDATA[HIV-1]]></category>
		<category><![CDATA[mother-to-child transmission]]></category>
		<category><![CDATA[PMTCT]]></category>
		<category><![CDATA[pregnancy]]></category>
		<category><![CDATA[Triple antiretroviral therapy]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/triple-antiretroviral-therapy-improves-pregnancy-outcomes/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – Besides preventing HIV-1 mother-to-child transmission (PMTCT), triple antiretroviral therapy during pregnancy improves pregnancy outcomes, according to findings published in the June 6th online AIDS. “All HIV infected women should receive triple antiretrovirals in pregnancy,” Dr. Karin Nielsen-Saines from David Geffen UCLA School of Medicine, Los Angeles, California told Reuters Health. -]]></description>
		
			<media:content duration="2:11" medium="video">
		<media:title><![CDATA[Triple antiretroviral therapy improves pregnancy outcomes]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – Besides preventing HIV-1 mother-to-child transmission (PMTCT), triple antiretroviral therapy during pregnancy improves pregnancy outcomes, according to findings published in the June 6th online AIDS. “All HIV infected women should receive triple antiretrovirals in pregnancy,” Dr. Karin Nielsen-Saines from David Geffen UCLA School of Medicine, Los Angeles, California told Reuters Health. -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/triple-antiretroviral-therapy-improves-pregnancy-outcomes/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4511.jpg"/>
	<media:keywords><![CDATA[AIDS,Dr. Karin Nielsen-Saines,HIV-1,mother-to-child transmission,PMTCT,pregnancy,Triple antiretroviral therapy]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
			<item>
		<title>Immediate ART not beneficial in HIV-related tuberculous meningitis</title>
		<link>http://www.thedoctorschannel.com/view/immediate-art-not-beneficial-in-hiv-related-tuberculous-meningitis/</link>
		<pubDate>Wed, 15 Jun 2011 16:03:00 +0000</pubDate> 
				<category><![CDATA[HIV/AIDS]]></category>
		<category><![CDATA[Hospitalist]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Internal Medicine]]></category>
		<category><![CDATA[Reuters Health • The Doctor's Channel Daily Newscast]]></category>
		<category><![CDATA[antiretroviral therapy]]></category>
		<category><![CDATA[art]]></category>
		<category><![CDATA[Clinical Infectious Diseases]]></category>
		<category><![CDATA[Dr. M. Estee Torok]]></category>
		<category><![CDATA[HIV]]></category>
		<category><![CDATA[TB]]></category>
		<category><![CDATA[tuberculous meningitis]]></category>
		<guid isPermaLink="false">http://new.thedoctorschannel.com/view/immediate-art-not-beneficial-in-hiv-related-tuberculous-meningitis/</guid>
		<description><![CDATA[NEW YORK (Reuters Health) – The dilemma of when to start antiretroviral therapy (ART) in patients presenting with tuberculous meningitis associated with HIV infection has been answered by the findings of a study conducted in Vietnam: immediate initiation of ART after starting TB therapy does not improve outcomes and adverse effects are worse than when -]]></description>
		
			<media:content duration="1:38" medium="video">
		<media:title><![CDATA[Immediate ART not beneficial in HIV-related tuberculous meningitis]]></media:title>
	<media:description><![CDATA[NEW YORK (Reuters Health) – The dilemma of when to start antiretroviral therapy (ART) in patients presenting with tuberculous meningitis associated with HIV infection has been answered by the findings of a study conducted in Vietnam: immediate initiation of ART after starting TB therapy does not improve outcomes and adverse effects are worse than when -]]></media:description>
	<media:player url="http://www.thedoctorschannel.com/view/immediate-art-not-beneficial-in-hiv-related-tuberculous-meningitis/collection/hiv-aids" />
		<media:thumbnail url= "http://www.thedoctorschannel.com/wp-content/uploads/2011/12/4444.jpg"/>
	<media:keywords><![CDATA[antiretroviral therapy,art,Clinical Infectious Diseases,Dr. M. Estee Torok,HIV,TB,tuberculous meningitis]]></media:keywords>
<media:copyright>The Doctor's Channel</media:copyright>
	</media:content>
			</item>
	</channel>
</rss>
